AbbVie Inc Market Cap ($356.49 Billion)
Market Cap & Net Worth: AbbVie Inc (ABBV)
AbbVie Inc market cap. AbbVie Inc (NYSE:ABBV) has a market capitalization of $356.49 Billion ($356.49 Billion) as of November 4, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #42 globally and #31 in its home market, demonstrating a 1.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AbbVie Inc's stock price $288.84 by its total outstanding shares 1768762377 (1.77 Billion). Also see AbbVie Inc (ABBV) cash conversion ratio for how efficiently the company converts equity into cash flow.
AbbVie Inc Market Cap History (2015–2026)
AbbVie Inc market cap history from 2015 to 2026. Data shows growth from $71.55 Billion to $510.89 Billion (20.06% CAGR). Check AbbVie Inc (ABBV) stock price for real-time trading data and today's change.
Index Memberships
AbbVie Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.14 Trillion | 31.14% | #1 of 39 |
|
ARCA Pharmaceutical
DRG
|
$3.45 Trillion | 10.34% | #3 of 24 |
|
S&P 500 Index
GSPC
|
$61.43 Trillion | 0.69% | #25 of 503 |
|
S&P 100
OEX
|
$44.08 Trillion | 0.98% | #24 of 101 |
Weight: AbbVie Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AbbVie Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AbbVie Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore AbbVie Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.61x
AbbVie Inc's market cap is 6.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
95.63x
AbbVie Inc's market cap is 95.63 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $78.55 Billion | $25.64 Billion | $5.95 Billion | 3.06x | 13.20x |
| 2017 | $125.74 Billion | $28.22 Billion | $5.31 Billion | 4.46x | 23.69x |
| 2018 | $124.54 Billion | $32.75 Billion | $5.69 Billion | 3.80x | 21.90x |
| 2019 | $126.37 Billion | $33.27 Billion | $7.88 Billion | 3.80x | 16.03x |
| 2020 | $161.40 Billion | $45.80 Billion | $4.62 Billion | 3.52x | 34.96x |
| 2021 | $213.73 Billion | $56.20 Billion | $11.54 Billion | 3.80x | 18.52x |
| 2022 | $265.04 Billion | $58.05 Billion | $11.84 Billion | 4.57x | 22.39x |
| 2023 | $264.42 Billion | $54.32 Billion | $4.86 Billion | 4.87x | 54.37x |
| 2024 | $314.31 Billion | $56.33 Billion | $4.28 Billion | 5.58x | 73.47x |
| 2025 | $404.14 Billion | $61.16 Billion | $4.23 Billion | 6.61x | 95.63x |
Competitor Companies of ABBV by Market Capitalization
Companies near AbbVie Inc in the global market cap rankings as of November 4, 2026. Also see AbbVie Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to AbbVie Inc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Novartis AG (MX:NVSN): Ranked #51 globally with a market cap of $319.66 Billion USD ( MX$5.55 Trillion MXN).
- Merck & Company Inc (NYSE:MRK): Ranked #54 globally with a market cap of $316.95 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1410.99 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #51 | Novartis AG | MX:NVSN | $319.66 Billion | MX$2911.00 |
| #54 | Merck & Company Inc | NYSE:MRK | $316.95 Billion | $148.36 |
Market Capitalization of AbbVie Inc (2015–2026)
Market capitalization of AbbVie Inc from 2015 to today. Between 2015 and today, AbbVie Inc's market cap moved from $71.55 Billion to $ 510.89 Billion, with a yearly change of 20.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $510.89 Billion | +26.41% |
| 2025 | $404.14 Billion | +28.58% |
| 2024 | $314.31 Billion | +18.87% |
| 2023 | $264.42 Billion | -0.23% |
| 2022 | $265.04 Billion | +24.01% |
| 2021 | $213.73 Billion | +32.43% |
| 2020 | $161.40 Billion | +27.72% |
| 2019 | $126.37 Billion | +1.47% |
| 2018 | $124.54 Billion | -0.96% |
| 2017 | $125.74 Billion | +60.07% |
| 2016 | $78.55 Billion | +9.79% |
| 2015 | $71.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of AbbVie Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $356.49 Billion USD |
| MoneyControl | $356.49 Billion USD |
| MarketWatch | $356.49 Billion USD |
| marketcap.company | $356.49 Billion USD |
| Reuters | $356.49 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more